By demonstrating that the KMO inhibitor Ro 61-8048 can simultaneously reduce seizures and improve depressive-like behaviors without exacerbating cognitive impairment, it reveals, for the first time, that targeting a single metabolic node can synergistically modulate neural excitability and mood loop dysfunction, providing a novel perspective on the mechanism of co-morbidity. The gene discussed is KMO; the disease is Cognitive impairment.